It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Speed and precision are essential in modern discovery. Sygnature Discovery’s High Throughput Chemistry platform gives you rapid access to custom, high-quality compound libraries that accelerate hit validation, hit-to-lead progression, and early optimization.
Sygnature brings unmatched experience in high-throughput chemistry, built on years of innovation and refinement.
Our advanced infrastructure and proven methodologies enable rapid delivery of diverse, drug-like molecules. Today, the internally developed LeadFinder Prism Collection exemplifies this capability, providing fast access to diverse compounds with high chirality and Fsp3 enrichment.
Our Cutting-Edge HTC Platform
To accelerate early-stage discovery and lead optimization, our HTC platform combines automation, innovation, and scalability. For clarity, we’ve grouped the capabilities into four key areas:
Fully Automated Workflows
Fully automated synthesis, purification, QC, and reformatting.
Robotic reformatting and QC reporting with full traceability.
Minimal manual intervention for speed and consistency.
Chemistry Compatibility
Broad reaction coverage across solvents, temperatures, and conditions.
Homogeneous and heterogeneous reaction support.
Glovebox-enabled protocols unlock our ability to run air sensitivity reactions in HTC mode.
Data & Design Tools
Comprehensive enumeration, filtering, and property-calculation workflows.
In-house libraries of reaction-ready, solubilized building blocks.
Automated cherry-picking for bespoke or hybrid libraries.
Purification & Screening
Custom mass -directed purification (ELS/UV options) via reverse -phase or SFC HPLC.
Dual purification systems for flexibility and scalability.
Reaction-to-assay screening in 96 – or 384-well formats.
Expertise in bi-functional degrader synthesis through CHARMED for rapid PROTAC screening.
With both reverse-phase and SFC platforms, we select the most effective purification route for every library ensuring purity and speed. Our proven experience in high-throughput synthesis supports direct-to-biology strategies, delivering reliable results and accelerating your project.
Automation That Accelerates Discovery
Our high-throughput chemistry platform combines expert-led design with advanced automation and parallel chemistry to deliver rapid, high-quality molecules. From library generation to purification, automation shortens design–make–test cycles and accelerates decision-making enabling faster, data-driven progression from concept to candidate.
Latest Technologies
Sygnature’s dual purification systems, reverse-phase and SFC, provide unmatched flexibility and scalability. Despite the complexity of SFC infrastructure, our in-house expertise ensures reliable, best-in-class separations under optimal conditions. With capacity for up to 300 injections per day and freeze-drying of 500+ samples, we deliver speed without compromise.
Success rate with internally validated monomer set
Automated cherry – picking system for bespoke or hybrid libraries
6,000 +
Monomers available, including 1,500+ solubilized acids and amines
Why Choose Sygnature Discovery for HTC Support?
Precision, speed, and collaboration drive everything we do. Our expert chemists combine deep experience with state-of-the-art automation to deliver tailored parallel synthesis, rapid purification, and data-rich results. With fast turnaround times and flexible scalability, we empower your teams to explore SAR efficiently and advance discovery with confidence.
At Sygnature Discovery, we have a long history of…
Posters
FAQs
On average it takes a little over a week from the initial enumeration to dried compounds in barcoded vials with QC data.
This can be tailored to specific client needs, but as standard we run 1 minute LCMS for all compounds.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Creative, scalable synthetic chemistry solutions using modern methodologies and advanced tools, transforming complex challenges into efficient, high-quality outcomes.
Clinically focused medicinal chemistry combining design excellence, AI-driven insight, and collaborative expertise to deliver molecules aligned with your goals.
Targeted Protein Degradation (TPD) is an innovative drug discovery approach focused on previously considered ‘undruggable’ proteins. TPD leverages the cell’s ubiquitin-proteasome system to tag these ‘undruggable’ proteins for degradation.
Integrated purification and analytical solutions using advanced SFC and HPLC delivering high-purity compounds from milligram to kilogram scale with confidence.
